Joris De Bie serves as the Head of Early Clinical Development at Chugai Pharmaceutical Co., Ltd., where he plays a pivotal role in advancing the company’s innovative therapeutic pipeline. With a wealth of experience in clinical development, Joris has successfully led teams through the complexities...
Joris De Bie serves as the Head of Early Clinical Development at Chugai Pharmaceutical Co., Ltd., where he plays a pivotal role in advancing the company’s innovative therapeutic pipeline. With a wealth of experience in clinical development, Joris has successfully led teams through the complexities of designing and executing early-phase clinical studies across a diverse range of therapeutic areas, including oncology, CNS disorders, women’s health, and inflammatory diseases. His strategic oversight ensures that all studies conducted in the U.S. align with Chugai’s global vision and regulatory standards, leveraging his deep understanding of Good Clinical Practice (GCP) and regulatory affairs.
As a member of the eDRC/EDST and chair of the Global Study Management platform, Joris collaborates with leaders from Chugai’s affiliates and headquarters to streamline processes and enhance operational efficiency. His expertise in change management and experience with mergers and acquisitions enable him to navigate the evolving landscape of the pharmaceutical industry effectively. Under his leadership, the Early Clinical Development Department at Chugai Pharma USA has not only expanded its capabilities but has also fostered a culture of innovation and excellence in clinical trial management.
Joris's proficiency in managing Contract Research Organizations (CROs) and his comprehensive knowledge of clinical pharmacology further bolster his ability to drive successful outcomes in clinical trials. His commitment to advancing medical science through rigorous research and development positions him as a key player in the pharmaceutical sector, dedicated to improving patient outcomes and bringing novel therapies to market.
